New hope for patients who run out of options: dual attack on tough lymphoma
NCT ID NCT07197307
Summary
This study is testing whether combining two newer lymphoma drugs, loncastuximab tesirine and epcoritamab, is safe and effective for people with aggressive B-cell lymphoma that has returned or not responded to prior treatments. It will enroll 120 adults whose disease has progressed after first-line therapy or after CAR-T cell therapy. The main goal is to see how many patients achieve significant tumor shrinkage or remission with this combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Münster, Medizinische Klinik A
Münster, 48149, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.